Emerging evidence indicates that chemokines can regulate both the physiology and biochemistry of CNS neurons and glia. In the current study, Western blot analysis showed that in rat hippocampal neuronal/glial cultures the signal transduction pathway activated by CCL2, a chemokine expressed in the normal brain and at elevated levels during neuroinflammation, involves a G-protein coupled receptor, p38 MAPK as well as its immediate upstream kinase MKK3/6, and the downstream transcription factor CREB. ERK 1/2 and the transcription factors STAT1 and STAT3 do not play a prominent role. CCL2 also altered Ca 2+ influx and synaptic network activity in the hippocampal neurons. These results suggest an important role for p38 MAPK and CREB in hippocampal actions of CCL2.
Introduction
The chemokine CCL2, a 14 kDa protein previously known as monocyte chemoattractive protein-1, was originally described in the immune system as a potent chemoattractant for monocytes and macrophages (Matsushima et al., 1989) . CCL2 and its primary receptor CCR2 are also widely expressed within the central nervous system (CNS), implicating roles for CCL2 in the CNS as well as in the immune system (Ambrosini and Aloisi, 2004; Bajetto et al., 2002) . Sources of CCL2 within the CNS include microglia and astrocytes, although some neurons can also produce CCL2 (Babcock et al., 2003; Banisadr et al., 2005a; Farina et al., 2007; Josselyn and Nguyen, 2005; Kielian et al., 2002; Weiss and Berman, 1998) .
Emerging evidence supports both physiological and pathological roles for CCL2 in the CNS. CCL2 expression in the normal CNS starts at an early stage of development, suggesting a physiological role for CCL2 in CNS development (Geppert, 2003; Meng et al., 1999) . However, a significant upregulation or dysregulation of CNS expression of CCL2 occurs in a variety of acute and chronic neuroinflammatory and neurodegenerative CNS disorders, implicating a role for CCL2 in pathological conditions. For example, CCL2 levels in the CNS are elevated in brain injury (Little et al., 2006) , cerebral ischemia (Che et al., 2001; Minami et al., 2006) , multiple sclerosis (Mahad and Ransohoff, 2003; McManus et al., 1998) , human immunodeficiency virus (HIV)-associated dementia (Cinque et al., 1998) and Alzheimer's disease (Galimberti et al., 2006) . Both neurotoxic and neuroprotective roles for CCL2 have been proposed in these conditions. CCL2 and other chemokines elicit their biological effects through interactions with G protein-coupled receptors. CCL2 preferentially binds to the chemokine receptor CCR2 (Bajetto et al., 2002) . Chemokine receptors are linked to a number of downstream signal transduction pathways that mediate their biological effects (Bajetto et al., 2002) . In immune cells, CCL2 signaling is reported to involve Gi/Go proteins and cellular calcium flux or activation of phospholipase C (Cambien et al.,
